# Trends in Antipsychotic Drug Use in the United States, 2000–2016

## TL;DR

This study analyzed antipsychotic drug use trends in U.S. hospitals from 2000 to 2016, showing a rise in atypical drugs and a decline in typical ones.

## Contribution

The study provides detailed insights into shifts in antipsychotic drug prescriptions and highlights persistent off-label use patterns.

## Key findings

- Atypical antipsychotic use increased while typical antipsychotic use decreased over the study period.
- Haloperidol and prochlorperazine were the most administered antipsychotics throughout the period.
- Quetiapine was the most prescribed atypical antipsychotic, followed by risperidone and olanzapine.

## Abstract

This study evaluated long-term trends in the prevalence of use of atypical and typical antipsychotic drugs (APDs), both as classes of drugs and as individual drugs, among adult inpatients in the United States (US). The Health Facts® database developed by Cerner Corporation was used to analyze the prevalence of APD use among adult inpatients aged 18 years or older who were administered at least one antipsychotic medication order during hospitalization between 1 January 2000 and 31 December 2016. The prevalence of APD use was standardized by age, sex, race, and census region. Typical and atypical antipsychotic treatment patterns in the US differed over this period. While the use of atypical APDs increased overall, the use of typical antipsychotic medications decreased, but remained more prevalent. Overall, haloperidol and prochlorperazine were the two most administered antipsychotic medications throughout the study period. From 2000 to 2011, prochlorperazine and haloperidol were the first- and second-most prescribed typical APDs, respectively; haloperidol became the most administered antipsychotic of this class as of 2012. Quetiapine was the most administered atypical antipsychotic medication, followed by risperidone and olanzapine until 2014, after which olanzapine was the second-most administered atypical APD. There was a notable decline in the use of atypical antipsychotics medications between 2005 and 2008, which may reflect the impact of the Food and Drug Administration’s warnings and the American Diabetes Association’s consensus position, but only for a short time. The usage patterns observed in this study support existing evidence of substantial off-label use of antipsychotic drugs in the US.